Heidy King-Jones sold $2.5M of SYRE
See Remarks at Spyre Therapeutics, Inc.. 28,399 shares at an average of $87.35, traded Sep 1, 2026, filed Sep 3, 2026.
Score components
- +15RoleOfficer
- +25Trade size$2.5M at market
- +20Share of holdings soldSold 92% of holdings
- +15Cluster3 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001636282-26-000111, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Sep 1, 2026 | MOption exercise Common Stock10b5-1 | +27,999 | $14.50 | $406k | 30,844 | 40 d ago |
| Sep 1, 2026 | SOpen-market sale Common Stock10b5-1 | -4,845 | $86.40 | $419k | 25,999 | 40 d ago |
| Sep 1, 2026 | SOpen-market sale Common Stock10b5-1 | -16,548 | $87.20 | $1.4M | 9,451 | 40 d ago |
| Sep 1, 2026 | SOpen-market sale Common Stock10b5-1 | -6,206 | $88.17 | $547k | 3,245 | 40 d ago |
| Sep 1, 2026 | SOpen-market sale Common Stock10b5-1 | -400 | $89.38 | $36k | 2,845 | 40 d ago |
| Sep 2, 2026 | MOption exercise Common Stock10b5-1 | +400 | $14.50 | $5,800 | 3,245 | 40 d ago |
| Sep 2, 2026 | SOpen-market sale Common Stock10b5-1 | -400 | $90.00 | $36k | 2,845 | 40 d ago |
| Sep 1, 2026 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -27,999 | $0.00 | $0 | 511,811 | 40 d ago |
| Sep 2, 2026 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -400 | $0.00 | $0 | 511,411 | 40 d ago |
Related signals
Other insiders at Spyre Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 37Weak | Spyre Therapeutics, Inc. | Scott L Burrows Chief Financial Officer | $2.3M 25,000 shares | -26% | |
| 40Moderate | Spyre Therapeutics, Inc. | Heidy King-Jones See Remarks | $2.6M 28,933 shares | -91% | |
| 45Moderate | Spyre Therapeutics, Inc. | Cameron Turtle Chief Executive Officer | $1.4M 15,000 shares | -3% | |
| 32Weak | Spyre Therapeutics, Inc. | Scott L Burrows Chief Financial Officer | $2.3M 25,732 shares | -24% | |
| 45Moderate | Spyre Therapeutics, Inc. | Cameron Turtle Chief Executive Officer | $1.3M 15,000 shares | -3% | |
| 25Weak | Spyre Therapeutics, Inc. | Jeffrey W. Albers director | $2.4M 23,000 shares | -460% | |
| 52Moderate | Spyre Therapeutics, Inc. | Scott L Burrows Chief Financial Officer | $1.3M 15,000 shares | -13% | |
| 75Notable | Spyre Therapeutics, Inc. | Fairmount Funds Management LLC director | $400M 4,684,781 shares | -100% | |
| 40Moderate | Spyre Therapeutics, Inc. | Michael Thomas Henderson director | $2.0M 20,000 shares | -23% | |
| 20Weak | Spyre Therapeutics, Inc. | Scott L Burrows Chief Financial Officer | $533k 7,500 shares | -7% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.